Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00366249 · ClinicalTrials.gov registry record · Phase 3
Study Evaluating the Safety and Efficacy of a Once-daily Dose of Tigecycline vs Ertapenem in Diabetic Foot Infections (DFI) With a Substudy in Patients With Diabetic Foot Infections Complicated by Osteomyelitis.
A Phase 3 study, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,061
- Enrollment target
NCT00366249 is a Phase 3 study that has completed, run by Wyeth is now a wholly owned subsidiary of Pfizer. The registered enrollment target is 1,061 participants.
The verdict
NCT00366249, a Phase 3 study, has completed, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,061 participants
- Enrollment target
Study Summary
The purpose of this study was to look at the safety and effectiveness of a once-daily dose of tigecycline compared to ertapenem for the treatment of diabetic foot infections. The co-primary efficacy endpoints were not met.
Interventions
- DRUG Ertapenem
- DRUG Tigecycline
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,061 participants |
| Start Date | 2007-01 |
| Est. Completion | 2009-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00366249
The ClinicalTrials.gov registry entry for NCT00366249 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,061 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Wyeth is now a wholly owned subsidiary of Pfizer, which has 167 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Ertapenem is the first listed.
NCT00366249 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00366249 about?
NCT00366249 is a clinical study titled "Study Evaluating the Safety and Efficacy of a Once-daily Dose of Tigecycline vs Ertapenem in Diabetic Foot Infections (DFI) With a Substudy in Patients With Diabetic Foot Infections Complicated by Osteomyelitis.". The purpose of this study was to look at the safety and effectiveness of a once-daily dose of tigecycline compared to ertapenem for the treatment of diabetic foot infections. The co-primary efficacy endpoints were not met.
What is the current status of trial NCT00366249?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,061 participants. The study started on 2007-01. Estimated completion is 2009-03.
What interventions are being tested in trial NCT00366249?
The interventions under investigation include: Ertapenem (DRUG), Tigecycline (DRUG).
Who is sponsoring clinical trial NCT00366249?
This trial is sponsored by Wyeth is now a wholly owned subsidiary of Pfizer, which has 167 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.